To the Editor I read with great interest the article by Munch-Petersen et al1 on a retrospective series of 100 patients with ocular adnexal diffuse large B-cell lymphoma (OA-DLBCL). The authors should be commended for their effort to investigate the role of staging systems and to establish survival figures in an uncommon malignant neoplasm for which relevant literature is sparse.2 The studied series was heterogeneous, including patients with primary OA-DLBCL, secondary OA-DLBCL, and relapsing disease with evident epidemiological disparities and treated with varied strategies. Nevertheless, this large series is an important tool to analyze some unsolved issues on the natural behavior and therapeutic management of these malignant neoplasms.